Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer
CONCLUSIONS: Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ BC. In addition, our study highlights the potential of increased MYC activity and intact P53 as predictors for sensitivity to CDK7 inhibitor-based treatments.PMID:38381406 | DOI:10.1158/1078-0432.CCR-23-2975 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 21, 2024 Category: Cancer & Oncology Authors: Cristina Guarducci Agostina Nardone Douglas Russo Zsuzsanna Nagy Capucine Heraud Albert Grinshpun Qi Zhang Allegra Freelander Matthew Joseph Leventhal Avery Feit Gabriella Cohen Feit Ariel Feiglin Weihan Liu Francisco Hermida-Prado Nikolas Kesten Wen Ma C Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19.PMID:38377732 | DOI:10.1016/j.breast.2024.103681 (Source: Breast)
Source: Breast - February 20, 2024 Category: Cancer & Oncology Authors: Gilles Freyer Noelia Martinez-Ja ñez Bo żena Kukielka-Budny Malgorzata Ulanska Hugues Bourgeois Montserrat Mu ñoz Serafin Morales Juan Bayo Calero Laura Cortesi Tam ás Pintér Mark éta Palácová Nelli Cherciu Edgar Petru Johannes Ettl C écilia de A Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19.PMID:38377732 | DOI:10.1016/j.breast.2024.103681 (Source: Breast)
Source: Breast - February 20, 2024 Category: Cancer & Oncology Authors: Gilles Freyer Noelia Martinez-Ja ñez Bo żena Kukielka-Budny Malgorzata Ulanska Hugues Bourgeois Montserrat Mu ñoz Serafin Morales Juan Bayo Calero Laura Cortesi Tam ás Pintér Mark éta Palácová Nelli Cherciu Edgar Petru Johannes Ettl C écilia de A Source Type: research
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19.PMID:38377732 | DOI:10.1016/j.breast.2024.103681 (Source: Breast)
Source: Breast - February 20, 2024 Category: Cancer & Oncology Authors: Gilles Freyer Noelia Martinez-Ja ñez Bo żena Kukielka-Budny Malgorzata Ulanska Hugues Bourgeois Montserrat Mu ñoz Serafin Morales Juan Bayo Calero Laura Cortesi Tam ás Pintér Mark éta Palácová Nelli Cherciu Edgar Petru Johannes Ettl C écilia de A Source Type: research
Cancers, Vol. 16, Pages 845: TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha
Todd W. Miller
Estrogen receptor alpha (ER)-positive breast cancer is responsible for over 60% of breast cancer cases in the U.S. Among patients diagnosed with early-stage ER+ disease, 1/3 will experience recurrence despite treatment with adjuvant endocrine therapy. ER is a nuclear hormone receptor responsible for estrogen-driven tumor growth. ER transcriptional activity is modulated by interactions with coregulators. Dysregulation of the levels of these coregulators is involved in the development of endocrine resistance. To identify ER interactors that modulate transcriptional activity in breast cancer, we utilized...
Source: Cancers - February 20, 2024 Category: Cancer & Oncology Authors: Bianca A. Romo Barbara Karakyriakou Lauren Cressey Brooke L. Brauer Huijuan Yang Alexa Warren Anneka L. Johnson Arminja N. Kettenbach Todd W. Miller Tags: Article Source Type: research
Changes in systemic cancer therapy in Australia during the Delta and Omicron waves of the COVID-19 pandemic (2021-2022): a controlled interrupted time series analysis
CONCLUSIONS: The 2021 lockdowns and 2021/2022 Omicron outbreaks in NSW and Victoria had significant impacts on the dispensing, initiation and discontinuation of systemic cancer therapies, however, the overall effects were minimal. The impacts of lockdowns were less significant than the Omicron outbreaks, suggesting COVID-19 infection, health system capacity, and patient and community concerns were important factors for treatment changes.PMID:38369711 | DOI:10.17061/phrp34012402 (Source: Cancer Control)
Source: Cancer Control - February 19, 2024 Category: Cancer & Oncology Authors: Forrest C Koch Monica Tang Ramesh Walpola Maria Aslam Sallie-Anne Pearson Benjamin Daniels Source Type: research
Should surgeons reconsider the role of intraoperative sentinel lymph node evaluation for premenopausal breast cancer patients in the era of RxPONDER?
Tremendous improvements in the role of personalized breast cancer care have resulted in paradigms shifts to treatment algorithms, particularly regarding the role of systemic chemotherapy in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The landmark TAILORx data demonstrated the utility and efficacy of the 21-gene recurrence score assay (Oncotype DX, Genomic Health) in women with HR-positive, HER2-negative, node-negative breast cancer as it demonstrated a statistically and clinically significant benefit to the receipt of adjuvant chemoendocrine therapy ...
Source: American Journal of Surgery - February 17, 2024 Category: Surgery Authors: Chandler S. Cortina, Amanda L. Kong Tags: My Thoughts / My Surgical Practice Source Type: research
Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
CONCLUSIONS: The findings of this cost-effectiveness analysis suggest that, at the current price of CTC enumeration, choosing first-line treatment options based on CTC count is a cost-effectiveness approach for treating patients with HR+/HER2- MBC in the US.PMID:38359563 | DOI:10.1016/j.breast.2024.103680 (Source: Breast)
Source: Breast - February 15, 2024 Category: Cancer & Oncology Authors: Huiting Lin Wenhua Wu Xiaoya Lou Yiming Wang Hong Sun Jiaqin Cai Suyan Liu Xiaoxia Wei Source Type: research
Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
CONCLUSIONS: The findings of this cost-effectiveness analysis suggest that, at the current price of CTC enumeration, choosing first-line treatment options based on CTC count is a cost-effectiveness approach for treating patients with HR+/HER2- MBC in the US.PMID:38359563 | DOI:10.1016/j.breast.2024.103680 (Source: Breast)
Source: Breast - February 15, 2024 Category: Cancer & Oncology Authors: Huiting Lin Wenhua Wu Xiaoya Lou Yiming Wang Hong Sun Jiaqin Cai Suyan Liu Xiaoxia Wei Source Type: research
